ANI Pharmaceuticals Inc (ANIP)
66.16
+0.59
(+0.90%)
USD |
NASDAQ |
Apr 23, 15:49
ANI Pharmaceuticals Research and Development Expense (Quarterly): 9.867M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 9.867M |
| September 30, 2023 | 11.12M |
| June 30, 2023 | 7.374M |
| March 31, 2023 | 5.924M |
| December 31, 2022 | 5.222M |
| September 30, 2022 | 7.657M |
| June 30, 2022 | 4.165M |
| March 31, 2022 | 5.274M |
| December 31, 2021 | 3.14M |
| September 30, 2021 | 2.456M |
| June 30, 2021 | 2.805M |
| March 31, 2021 | 2.968M |
| December 31, 2020 | 3.683M |
| September 30, 2020 | 2.939M |
| June 30, 2020 | 3.035M |
| March 31, 2020 | 6.344M |
| December 31, 2019 | 4.678M |
| September 30, 2019 | 4.982M |
| June 30, 2019 | 5.773M |
| March 31, 2019 | 4.373M |
| December 31, 2018 | 3.482M |
| September 30, 2018 | 4.667M |
| June 30, 2018 | 5.137M |
| March 31, 2018 | 2.102M |
| December 31, 2017 | 2.651M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.634M |
| June 30, 2017 | 2.167M |
| March 31, 2017 | 1.618M |
| December 31, 2016 | 0.135M |
| September 30, 2016 | 1.041M |
| June 30, 2016 | 0.764M |
| March 31, 2016 | 0.966M |
| December 31, 2015 | 0.661M |
| September 30, 2015 | 0.815M |
| June 30, 2015 | 0.995M |
| March 31, 2015 | 0.403M |
| December 31, 2014 | 0.568M |
| September 30, 2014 | 0.883M |
| June 30, 2014 | 0.851M |
| March 31, 2014 | 0.376M |
| December 31, 2013 | 0.524M |
| September 30, 2013 | 0.454M |
| June 30, 2013 | 0.437M |
| March 31, 2013 | 0.972M |
| December 31, 2012 | 2.435M |
| September 30, 2012 | 3.873M |
| June 30, 2012 | 5.398M |
| March 31, 2012 | 5.183M |
| December 31, 2011 | 6.701M |
| September 30, 2011 | 11.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.456M
Minimum
Sep 2021
11.12M
Maximum
Sep 2023
5.232M
Average
4.982M
Median
Sep 2019
Research and Development Expense (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 5.488M |
| ADMA Biologics Inc | 0.4455M |
| Dentsply Sirona Inc | 43.00M |
| Allogene Therapeutics Inc | 54.66M |
| Vanda Pharmaceuticals Inc | 24.34M |